1. Home
  2. JXN vs ERAS Comparison

JXN vs ERAS Comparison

Compare JXN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jackson Financial Inc.

JXN

Jackson Financial Inc.

HOLD

Current Price

$134.25

Market Cap

7.5B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$18.17

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JXN
ERAS
Founded
1961
2018
Country
United States
United States
Employees
N/A
103
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
6.3B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
JXN
ERAS
Price
$134.25
$18.17
Analyst Decision
Hold
Strong Buy
Analyst Count
5
12
Target Price
$112.40
$14.25
AVG Volume (30 Days)
543.8K
3.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
3.13%
N/A
EPS Growth
N/A
36.23
EPS
2.98
N/A
Revenue
$6,683,000,000.00
N/A
Revenue This Year
$15.15
N/A
Revenue Next Year
$3.44
N/A
P/E Ratio
$44.79
N/A
Revenue Growth
104.31
N/A
52 Week Low
$89.67
$1.33
52 Week High
$137.99
$24.28

Technical Indicators

Market Signals
Indicator
JXN
ERAS
Relative Strength Index (RSI) 61.46 53.57
Support Level $128.97 $17.36
Resistance Level $137.55 $18.71
Average True Range (ATR) 3.08 1.16
MACD -0.43 0.06
Stochastic Oscillator 66.24 43.08

Price Performance

Historical Comparison
JXN
ERAS

About JXN Jackson Financial Inc.

Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail product offerings are comprised of annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. The company manages its business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments. The company generates the majority of its revenue from the Retail Annuities segment, which offers a variety of retirement income and savings products of variable annuities, registered index-linked annuities ("RILA"), fixed index annuities, fixed annuities, and payout annuities.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: